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Case description
A 23-year-old male patient was referred to the Department of 
Ophthalmology at Tygerberg Academic Hospital (TAH) after failing 
a routine driver’s licence eye test. He had noticed gradual visual 
deterioration of his right eye over the preceding months down to a 
visual acuity of 6/20 but was otherwise asymptomatic. Detailed eye 
examination detected bilateral retinal haemangioblastomas.
In 1999 the patient was diagnosed at TAH with a phaeochromocytoma, 
after presenting with a hypertensive crisis. A single right adrenal 
phaeochromocytoma was localised with the use of computed 
tomography (CT) and metaiodobenzylguanidine (MIBG) scanning. 
Total right adrenalectomy was performed, and histology confirmed 
the presence of two discrete phaeochromocytomas in the same 
adrenal gland. The patient became normotensive after surgery and 
was lost to follow-up.
At the current presentation he was again found to be hypertensive, 
with fluctuating blood pressure measurements between 110/60 
mmHg and 180/110 mmHg. In addition, left ventricular hypertrophy 
was found to be present by echocardiogram. Three 24-hour urine 
collections for catecholamine determination showed consistent 
elevation of normetadrenaline (NMA) and vanillylmandelic acid (VMA). 
A MIBG scan confirmed the presence of a phaeochromocytoma in his 
left adrenal (see Figure 1). A CT scan demonstrated the presence of 
a large left adrenal mass (see Figure 2) of 65 mm by 25 mm; no other 
tumours in his abdomen or chest cavity could be demonstrated. 
The presence of haemangioblastomas with multiple phaeochromo-
cytomas suggested the diagnosis of VHL disease, and further 
investigations were performed to search for other components of 
this disease. On magnetic resonance imaging (MRI) of the patient’s 
brain, a small midbrain haemangioblastoma (see Figure 3) was found 
but no tumours of the endolymphatic sac of his middle ear. Nine 
asymptomatic spinal cord haemangioblastomas from C2 to L1 were 
also detected. No epididymal tumours were detected with ultrasound 
scanning, and a CT scan of his kidneys and pancreas failed to show 
any cystic or solid lesions. 
Introduction
A young man was diagnosed with Von Hippel-Lindau (VHL) disease. We report the details of his case and review the relevant literature.
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Figure 1: MIBG scan confirming a single left phaeochromocytoma (arrows)
Figure 2: CT scan demonstrating the large left adrenal mass (arrows)
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Blood pressure control was achieved by the initial use of doxazosin, 
with subsequent addition of propranolol. Elective laparoscopic left 
total adrenalectomy was performed. Once stable the patient was 
changed to maintenance oral hydrocortisone and fludrocortisone. 
The patient was discharged, with advice to attend follow-up 
that will involve annual screening for the development of other 
components of VHL disease. This includes a CT scan of his kidneys 
and pancreas, measurement of urinary catecholamines and MRI 
of his brain and whole spinal cord. Surgical management of the 
right retinal haemangioblastoma was successful; the left retinal 
haemangioblastoma underwent spontaneous resolution with the 
formation of fibrosis. Management of the midbrain and spinal cord 
haemangioblastomas is conservative at present. 
The patient was referred for genetic counselling and genetic testing 
and was informed about the heredity of this condition. Genetic testing 
confirmed the presence of a germ-line mutation on chromosome 3 
(VHL gene) with an in-frame 3 base-pair (GAT) insertion in exon 2 at 
codon 378. His family members are being tested for this mutation. 
His father (aged 60) was found to have multiple spinal cord and 
retinal haemangioblastomas, in keeping with familial VHL disease.
Review of the literature
Several diseases are associated with hereditary phaeochromo-
cytomas including VHL disease, multiple endocrine neoplasia (MEN) 
types 2A and B, and neurofibromatososis type 1.1 A genetic cause 
should be considered in young patients presenting with sporadic 
phaeochromocytomas; in patients with a positive family history; in the 
case of multiple, bilateral or malignant phaeochromocytomas; in the case 
of clinical features suggestive of one of the familial diseases 
associated with phaeochromocytoma; or in the case of sympathetic 
paragangliomas.1
VHL disease is an autosomal dominant syndrome associated with 
a variety of benign and malignant tumours.2 Characteristic tumours 
are haemangioblastomas of the eyes or the central nervous system; 
clear cell renal carcinomas; phaeochromocytomas; endolymphatic 
sac tumours of the middle ear; serous cysts, cyst adenomas and 
neuroendocrine tumours of the pancreas; and papillary cystadenomas 
of the epididymis and broad ligament.2,3 
The VHL gene abnormality is present in 1/36 000 births and has 
a high penetrance.2,3 Initial manifestations can occur at any age, 
with a mean age at presentation of 26 years.4 The VHL gene has 
been mapped to the short arm of chromosome 3 (3p25–26). The 
product, Von Hippel-Lindau protein (pVHL), is a tumour suppressor 
protein.2-4 Hypoxia-inducible factor (HIF) plays an important role in 
the pathogenesis of the vascular tumours in VHL disease.4-7 Hypoxic 
cells or cells lacking pVHL accumulate high levels of HIF, leading to 
production of several growth factors, including vascular endothelial 
growth factor, platelet-derived growth factor beta, transforming 
growth factor alpha and erythropoietin. This is an important step in 
the development of highly vascular tumours.2,5,7 
Central nervous system (CNS) and retinal haemangioblastomas 
are usually the first presenting lesions in VHL disease.3 CNS 
haemangioblastomas are well-circumscribed, vascular, benign 
tumours that cause symptoms through local pressure or through 
haemorrhage and can be a major cause of morbidity and physical 
disability. CNS haemangioblastomas are usually infra-tentorial, the 
majority occurring in the spinal cord and in the cerebellum; less 
common sites are the brain stem and supratentorial.8 Small lesions 
can be managed with careful surveillance, with surgery reserved for 
symptomatic lesions.9 Stereotactic radiosurgery and conventional 
fractionated radiation therapy are also used, but long-term outcome 
is unknown.8 
Retinal angiomas or haemangioblastomas affect up to 70% 
of patients; they are often multifocal and bilateral and may 
haemorrhage, leading to retinal detachment, glaucoma, cataracts, 
uveitis, macular oedema or loss of vision.2,3 Treatment of retinal 
lesions includes laser photocoagulation or cryotherapy, with the 
exception of haemangioblastomas of the optic nerve.2-4 Vitrectomy 
or external beam radiotherapy can be utilised for certain indications, 
and vascular endothelial growth factor receptor inhibitors are gaining 
ground as novel therapy for this condition. 2,10 
Phaeochromocytomas occur on average in 10–20%2 of patients 
with VHL disease.11 They are often multiple, bilateral or extra-
adrenal (12%), and VHL patients tend to be younger than patients 
with sporadic phaeochromocytomas (mean age of presentation is 
30 years).2 Phaeochromocytomas in VHL disease are less likely to 
Figure 3: MRI of brain demonstrating a small 
midbrain haemangioblastoma (arrows)
Diagnostic criteria for VHL disease 2,3
Positive family history, with one of the following:
–  CNS or retinal haemangioblastoma
–  Phaeochromocytoma
–  Clear cell renal carcinoma
Negative family history, with one of the following:
–  Two or more haemangioblastomas (CNS or retina)
–  One haemangioblastoma + a visceral tumour (excluding renal and 
epididymal cysts)
98
Case Report:  A patient with multiple phaeochromocytomas and visual loss
2009 Volume 14 No 2JEMDSA
be associated with symptoms and are less likely to be biochemically 
active than sporadic phaeochromocytoma; up to 35% of VHL 
patients are asymptomatic.11,12 Prior to any surgery or pregnancy, all 
patients with VHL disease have to undergo preoperative screening 
for occult phaeochromocytomas to avoid the risk of a perioperative 
hypertensive crisis.2 Surgical excision is preferably laparoscopic with 
an attempt made to perform cortical-sparing surgery.2,3,8
Several surveillance strategies for patients with VHL disease have been 
published.3,8 Genetic counselling is important for affected families 
and especially for those where the index case has an identifiable 
VHL disease gene mutation.3,8 The progress in genetic testing has 
resulted in members of the family without the gene mutation now 
being exempted from the rigorous screening protocols.8 
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